Press Room

There are 3 item(s) tagged with the keyword "Lucentis".

1. JDRF Applauds FDA''s Approval of Lucentis to Treat Diabetic Macular Edema

JDRF is pleased by the U.S. Food and Drug Administration's (FDA) announcement today that it has approved the drug Lucentis (ranibizumab injection) for the treatment of diabetic macular edema (DME)-a major complication of diabetes and a leading cause of significant vision loss and blindness in adults...


2. Diabetic Macular Edema Clinical Trial Results Announced

NEW YORK, April 28, 2010 - A Phase II clinical trial showed that a drug combined with the current standard treatment of laser therapy is more effective than the current medical treatment in treating diabetic eye disease for people with type 1 and type 2 diabetes.


3. JDRF-Funded Treatment for Diabetic Eye Disease Moves Ahead to Regulatory Review in Europe

NEW YORK, Dec. 10, 2009 -- A promising drug for diabetes-related eye disease has moved along the drug development pipeline considerably ahead of schedule in Europe.


Lets turn type one into type none